Europe Prothrombin Complex Concentrate Market to Grow USD 398.9 Million at 10.9% CAGR till 2027; Rising Adoption of Advanced Bleeding Disorder Management Solutions to Fuel Growth: Fortune Business Insights™ Top Players Covered in the Europe Prothrombin Complex Concentrate Market Research Report are Takeda Pharmaceutical Company Limited (Tokyo, Japan), Kedrion S.p.A (Lucca, Italy), Grifols, S.A. (Barcelona, Spain), Sanquin (Amsterdam, The Netherlands), Octapharma AG (Lachen, Switzerland), CSL Limited (Melbourne, Australia) and other key market players.
February 09, 2021 04:48 ET | Source: Fortune Business Insights Fortune Business Insights
Pune, India, Feb. 09, 2021 (GLOBE NEWSWIRE) The
Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027, exhibiting a CAGR of 10.9% during the forecast period. The substantial advantages offered by prothrombin complex concentrate (PCC) will be the prim
Takeda logra la neutralidad de carbono en 2020 pmfarma.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmfarma.es Daily Mail and Mail on Sunday newspapers.
717.5
-3.8%
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at
(2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations.
(3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
ABS120,
ABS185].
About Hemophilia
Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.
4 Hemophilia A is more common than hemophilia B; in 2018, hemophilia A affects about 173,711 people, whereas hemophilia B affects about 34,289 people worldwide.
5
People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.
6 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.
7
About Takeda Hematology
Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real-world experience. We have 70+ years driving innovation for patients